

Medivir Q4 2022 - Fostrox One Step Closer to Phase IIa

Redeye comments on Medivir's fourth quarter report. We expect fostrox's dose escalation study to finish shortly, after which the phase IIa part can commence.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Medivir Q4 2022 - Fostrox One Step Closer to Phase IIa](#)